JUMPSEAT
AEROSPACE NEWS

Tariffs Reshape Pharma Supply Chains

Key Takeaways
  • Tariffs and geopolitics disrupt pharma supply chains.
  • 30% of life sciences companies cite supply chain disruption as primary challenge.
  • 26% point to tariff uncertainty and high supply costs.
Sign in to view key takeaways Get full access to in-depth analysis and key takeaways.
Sign In
Silver membership required Upgrade to Silver to access Key Takeaways.
Upgrade
Strategic Implications

The combination of tariffs and geopolitics may indicate a long-term shift in global trade policies, which could force life sciences companies to reassess their supply chain strategies and investments. This uncertainty suggests a need for increased agility and diversification in sourcing and logistics, which may benefit companies that adapt quickly to changing market conditions.

Sign in to view strategic implications Get full access to strategic analysis and expert insights.
Sign In
Silver membership required Upgrade to Silver to access Strategic Implications.
Upgrade

What Happened

Life Sciences Companies Face Growing Uncertainty

A new survey from AlixPartners found that supply chain disruption has become a top challenge for life sciences companies, with nearly 30% of respondents citing it as their primary pain point. The findings come as pharmaceutical manufacturers and medical device companies face growing uncertainty around tariffs, sourcing, and global trade. According to the report, policy shifts, competitive pressures, and supply chain disruptions are major contributors to sustained margin compression, weakening the sector’s historical pricing power, as reported by Logistics Management.

Source

Advertisement 728 × 90
JUMPSEAT
AEROSPACE NEWS
JUMPSEAT
AEROSPACE NEWS

Tariffs Reshape Pharma Supply Chains

Sponsored by: Jumpseat Solutions
Key Takeaways
  • Tariffs and geopolitics disrupt pharma supply chains.
  • 30% of life sciences companies cite supply chain disruption as primary challenge.
  • 26% point to tariff uncertainty and high supply costs.
Sign in to view key takeaways Get full access to in-depth analysis and key takeaways.
Sign In
Silver membership required Upgrade to Silver to access Key Takeaways.
Upgrade
Strategic Implications

The combination of tariffs and geopolitics may indicate a long-term shift in global trade policies, which could force life sciences companies to reassess their supply chain strategies and investments. This uncertainty suggests a need for increased agility and diversification in sourcing and logistics, which may benefit companies that adapt quickly to changing market conditions.

Sign in to view strategic implications Get full access to strategic analysis and expert insights.
Sign In
Silver membership required Upgrade to Silver to access Strategic Implications.
Upgrade

What Happened

Life Sciences Companies Face Growing Uncertainty

A new survey from AlixPartners found that supply chain disruption has become a top challenge for life sciences companies, with nearly 30% of respondents citing it as their primary pain point. The findings come as pharmaceutical manufacturers and medical device companies face growing uncertainty around tariffs, sourcing, and global trade. According to the report, policy shifts, competitive pressures, and supply chain disruptions are major contributors to sustained margin compression, weakening the sector’s historical pricing power, as reported by Logistics Management.

Source

Advertisement 300 × 250 Google AdSense